UCP2 and metabolic dysfunction-associated steatohepatitis: Protectively, treatment with BM-MSCs-EV (120 μg/kg) and BM-MSCs significantly increased UCP2 gene expression by 5- and 3.5-fold, respectively, accompanied with significant increase in MnSOD gene expression by 11- and 9-fold, respectively, as compared to cardiotoxicity induced by NASH group (Figure 6A,B).